Cbio A/S – enabling cancer cure



Enabling cancer cure

Cbio’s mission is to develop and bring next-generation T-cell therapies to cancer patients worldwide.
Cancer is by far the biggest unmet need of our time. At Cbio, we are working with T-cell therapies that is recognized to be the most promising therapy against late-stage solid cancers. T-cell therapies are 'living drugs' and will transform the way cancer patients are being treated with the aim not just to extent survival of these patients - but to make them cancer free.  


REVITA technology platform

Cbio’s unique and proprietary REVITA technology platform provides a clearly differentiated T-cell therapy product with transformative potential – a product designed to revitalize resting immune cells, securing a highly potent multitargeted T-cell product that effectively tracks down and kills cancer cells.
The REVITA technology platform benefits from the breakthrough discovery that ex-vivo checkpoint inhibition and stimulation can generate a broader T-cell repertoire of more stemness-like T-cells thereby leaving less opportunities for the cancer to escape attacj from the immune system.


Our first product - novoleucel

Cbio’s first product, novoleucel, is a broad spectrum T-cell therapy product designed to target and eradicate tumor cells all over the body leaving less opportunities for the cancer to escape. Targeting late-tage cancer patients, novoleucel offers a new hope for survival and possible cure for patients that have exhausted all other treatment alternatives.
Cbio has finalized the preclinical development for novoleucel in cervical cancer and expects to enter clinical development at Karolinska in Stockholm in early 2024.


Join our team in the quest for curing cancer

Join us in the fight to make cancer a curable disease together with our collaborators and partners. Cbio offers you the possibility to truly make an impact and where your dedication, contributions and opinions are highly valued. 



Ulrik Cordes

Founder, Chief Executive Officer

Business focused leader with 25 years’ experience in biotech and pharma.

Read more

Cecilia Hultén

Co-founder, Chief Financial Officer

Finance executive, entrepeneur and investor with extensive experience from capital markets and the startup scene.

Read more

Jørgen Dam

Co-founder, Chief Operating Officer

Jørgen has a profound experience in strategic and operational leadership within biotech and pharma.

Read more